Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGINA: Neoadjuvant Regorafenib and Nivolumab with SCRT in Rectal Cancer
NCT04503694Phase 2Active, not recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and regorafenib in rectal cancer, sponsored by Institut Jules Bordet. Primary endpoint: Efficacy of the combination of nivolumab and regorafenib. Started Mar 2021; status: active, not recruiting.
02
Drugs
nivolumabregorafenib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04503694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503694.